Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Look at the author's list of articles. The only company in this space he speaks favorably of is Canopy - gee - showing his true colors.
And this is poor writing and analysis. Is this a college kid writing this?
Waiting for the bottom then buying a lot more.
ADMINS: How can you not block this guy after this post? He's blatantly lying and spreading falsehoods. It's absurd.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=151206012
I'm about to buy more. I may wait until later in the day, or tomorrow.
The fundamentals are strong and they have done, and continue to do a great job cleaning their reputation and embracing being an industry leader.
If you're a fundamental investor, this is the find of the year. I'm holding long.
CNN: Aurora buying US CBD company in likely move
- Says Aurora is going to buy a US CBD company
- Says Aurora has been doing a "review tour" of US CBD companies (maybe these were the "suits in the CVSI offices" a previous poster was talking about)
This is a very revealing article:
Aurora Cannabis' next big play: The US CBD market
https://www.cnn.com/2019/09/12/business/aurora-cannabis-earnings-cbd/index.html
San Francisco (CNN Business)Aurora Cannabis is angling to become the world's leading cannabis company, and the Canadian operator's next big move could come south of its border.
Aurora (ACB) plans to aggressively pursue the United States cannabis market with an acquisition in the hemp-derived CBD space as its likely first big play.
"We expect to have a significant footprint in the US in the coming quarters," Aurora chairman Michael Singer told CNN Business on Thursday.
US sales of products containing hemp-derived cannabidiol, commonly known as CBD, have boomed following last year's passage of the Farm Bill, which legalized hemp. The bill also left CBD to the purview of the US Food and Drug Administration, which is still reviewing how or if products that contain CBD can be consumed.
Aurora entered the US CBD space earlier this year via a multiyear research partnership with the Ultimate Fighting Championship.
While several Canadian licensed producers have landed high-profile American investors — Corona maker Constellation Brands (STZ) in Canopy and Marlboro maker Altria (MO) in Cronos Group (CRON) — Aurora has been noticeably absent from such billion-dollar deals.
Aurora has conducted a "review tour" of America's multi-state cannabis operators and is leveraging the contacts of new strategic advisor Nelson Peltz in those efforts, Singer said. Peltz, the billionaire activist investor, has also set up conversations between Aurora and several companies in other industries for potential future partnerships, said Singer in an interview Thursday following Aurora's fiscal fourth-quarter earnings call.
Aurora's stock fell more than 9% on the results, which included a C$2.3 million net loss and quarterly revenue of C$98.9 million, which missed analyst estimates and its own guidance of C$100 million to C$107 million. For the year, Aurora reported a net loss of C$290.8 million and revenue net of excise taxes of C$247.9 million amid investments to build out production and a slow-to-develop Canadian retail market.
"I think that the [market's reaction] is surprising, and I don't really understand it looking for profit really early in the lifestage of these companies," said Kristoffer Inton, a Morningstar analyst who tracks Aurora, Canopy and other leading cannabis companies. "From my perspective, it was a good quarter."
The performance Thursday continued a trend of Wall Street not reacting favorably to cannabis companies' near-term losses. After Canopy's earnings triggered investor uncertainty, interim CEO Mark Zekulin last week went on a media blitz to shore up investor faith in the business.
CLASSIC! (video:
If you are up for organizing the poll like you have with the quarterly earnings - that would be fun to get a sense of where the longs stand. Suggested criteria below but obviously others may have suggestions.
People should enter:
1. Minimum buyout price that they would be 'ok' with
2. Middle buyout price that would get them a little bit excited
3. Top buyout price that would make them ecstatic
4. Timeline that they think their targets would be achievable
5. A brief summary, from 1 sentence to 3 paragraphs, of what they are basing their numbers on. Examples include 50 day MA, 100 day MA, industry outlook, their timeline tolerance for this stock, industry multiple, more or less upcoming competition, patent process, etc.
This would also add some good basis for research and probably add a lot of information for new potential investors.
What do you think? You up for organizing it? It's a little more involved but obviously feel free to simplify it if you want!
Great! Risk that anyone would do anything with it/you is minimal, but you can never be too careful today.
You don't want to be publicly giving out your IP address...
Link worked fine for me.
Most sales don't get done on "potential." They get done on revenues and industry multiples. Is there a value to the process they have started (not completed)?
% liklihood patent gets issued? Only IP industry professional would know, which I am not.
Agree with zizzy lol. However, it's fun to see what everyone is ok with for a buyout. We should actually do a poll. Where is SpaceLady when you need her!?
I'd be happy with $8-$12. I have a lot of money in CVSI and there is a lot of opportunity in the market right now. I'd be a little disappointed we never got to $20 but that's ok. We can't let perfect be the enemy of good.
However, given the low share price right now, CVSI's relative standing to other players with relatively similar financials, I wonder what a valuation would look like.
This company has a lot of potential for going up in the industry, but also a lot of opportunity to get squashed by large multi-nationals.
It's fun to speculate on a big return like a buyout, however, for all we know, this could just be made up info.
They have 50 brands on here and CVSI is in the very middle. They say nothing bad about any of the brands.
...zzzz....
I'm long.
MORE Industry News: NFL'er Rob Gronkowski partners with CBD company, CBDMedic
CNN: https://www.cnn.com/2019/08/27/us/rob-gronkowski-cbd/index.html
Company website: https://cbd-medic.com/Gronk
Industry News: Fmr. Trump Acting Attorney General Joins Cannabis Company As Legal Advisor
He's a big CBD supporter says the article.
https://www.marijuanamoment.net/former-trump-acting-attorney-general-joins-cannabis-company-as-legal-advisor/
A former acting attorney general for the United States is joining a cannabis company as outside counsel, the firm announced on Tuesday.
Matthew Whitaker, who served as the country’s top cop for three months after Jeff Sessions resigned from the Department of Justice in November 2018, has previously voiced support for CBD and said that he personally knows individuals who’ve benefited from the non-intoxicating compound.
Now he’ll be in a position to advance the interests of the CBD industry at Alternate Health, which distributes and manufacturers hemp-derived cannabidiol products.
“I am looking forward to taking on a new challenge with Alternate Health, strategically advising the Company and its management team,” Whitaker said in a press release. “I think there is serious potential in the CBD industry, and everyone at Alternate Health will work hard to be a leader in the industry.”
Alternate Health CEO Howard Mann said that Whitaker’s experience in the Justice Department and testifying before Congress will “open doors at many of the most important institutions concerning our industry.”
The company’s president added that the “legal environment surrounding CBD is rapidly evolving and it is essential that Alternate Health stays at the forefront of new government and FDA regulations” and that Whitaker will help them get to that place.
During his time at acting attorney general, Whitaker did not take adverse action against state-legal marijuana programs and did not show the open hostility to cannabis consumers that his predecessor did.
In fact, he said in February that he proactively worked to expand the number of federally authorized marijuana manufacturers for research purposes, though also acknowledged that he didn’t have enough time left in his position “to successfully get to it.” (The Drug Enforcement Administration announced on Monday that it is taking steps to get grower applications approved.)
Whitaker was replaced by William Barr, who also said he supports the expansion and even said in April that he’d prefer for Congress to pass legislation allowing states to set their own marijuana policies rather than continue with the status quo of conflicting state and federal cannabis laws.
Ah! Very nice!
Always meant to ask. That bay picture in your signature...you a sailor? Looks an awful like a bunch of bays I frequent twice a year.
I'm not too worried about CVSI long-term either. Just pointing out why we may be missing from that recommendation newsletter.
One of my previous plays on the OTC was in an industry that was completely and 100% illegal in every way, shape and form, then became legal. A lot of similarities here.
They are on big boards. Being on the OTC would disqualify CVSI from being recommended by most legitimate stock trading newsletters.
I did. 3.07 and 3.11. Bought more to add to my long position.
It was falling for one simple reason: The OTC is an extremely volatile platform that is exponentially less rational than the big boards due to the fact that the people who maintain rationality on the big boards (funds and institutions) do not invest in OTC. Therefore, OTC is subject to extreme manipulation by day traders, swing traders and other risk-taking short-term traders.
I've invested, non-exclusively, on the OTC in companies through a very specific set of guidelines I've developed over the 15 years on the OTC. The OTC is actually very predictable if you trade in companies based on your own guidelines. You'll see that different types of companies are generally manipulated the same way.
I've invested in multiple companies that were good companies, in regulatory ambiguous industries, then uplisted to NYSE or NASDAQ. When they were on the OTC, they all follow the same trends in terms of stock price, manipulation and message board reactions to each event.
I really like CVSI. But as I tell everyone, when investing on OTC, be psychologically prepared to lose every cent you put here. Company fraud IS rampant on OTC. My first investment on OTC I lost everything I had in that company.
I do think CVSI has the magic that I've hit with a few other OTC companies uplisting.
If you invest long enough, this is a very obvious answer. Not a dig at anyone, just comes with decades of experience.
Hedge funds absolutely have investing rules - typically set by or influenced by governance standards of which their investors hold the funds accountable by.
You may be conflating family offices with hedge funds.
It's 1000% a thing. I should have been more clear. I'm specifically talking about institutions investing in CVSI - not analysts initiating coverage (which is a completely different universe).
Don't hold your breath. I'm very long however, we've seen these types of jumps before. No matter what, as long as we are on the OTC, this stock will continue to be very volatile.
Yes there are good signs like Piper covering CVSI now, but the fact is that we are still on the OTC and institutions won't touch it until they are on NASDAQ. Until then, this will continue to be manipulated - period end of story.
He got the market cap of CWEB completely wrong! It's over $2 billion, right?
They should not, under any circumstance, change their brand, brand name or deviate away from their very successful brand progress.
That is TEXTBOOK, amateurish mistake. They literally teach this in schools still.
If your brand has no problems, and it's successful don't change it! Lean into it.
I pray they don't do something as stupid as to mess with their branding.
While Piper target is a nice milestone for this company, remember that we are still on OTC and this SP will probably still not act rationally. We have targets already out there and they had no effect on long-term SP.
While Piper is reputable, OTC is not and the manipulators are still here waiting for another opportunity to play this fiddle.
The only thing that is going to catapult this thing back up to $6-$10 and beyond is FDA providing regulatory clarity and then subsequently, hopefully a NASDAQ uplisting. OR another unexpected knockout earnings, which isn't going to happen. The growth path of this company is more and more a known quantity.
I'm long and strong. Bought a lot more last week under $3.10.
I hope they all make their $100 - $2,000 dollars as they lose it again on another trade as they move on from CVSI ha. All these poor day traders, losing their money long term as it drip, drip, drips away.
I'm long here with CVSI but I agree, CW is the clear leader. In financial markets, money tells you who is winning and their market cap (2.5B), along with their access to exponential more capital, says it all.
I think CVSI started with a bad reputation, is stuck on OTC and is being manipulated as a result and is working hard to clean itself up. If they get on NASDAQ, they could fly. We could all fly.
CVSI is primed very well, but they are only primed, they aren't 'there' yet when it comes to what counts: The reputation and access to institutional investors and the pedigree that being on a big board or having a clean image, brings.
They could be and that's what we are all investing in.
But for now, CW is clear leader.
I agree with this post. Online DTC sales are imperative. They should even have a mobile app just like Nike, Under Armour and others, for CBD news and products.
I think Dowling was alluding to this issue when he talked about revamping their online store in the letter.
Hire a PPC firm and make it rain in the states that allow it.
Re: Letter from CEO
Good letter. States everything there in one place, finally. It won't solve the share price problem but it's a good gesture, regardless. Only moving up to NASDAQ will solve the OTC manipulation happening here on this exchange. Here's the link and full text below my comments:
https://ir.cvsciences.com/press-releases/detail/125/cv-sciences-inc-ceo-issues-letter-to-shareholders
About special legal counsel: Real companies hire specialized legal counsel for everything, having done it myself many times. This is good news.
Some people on this board don't know what they are talking about and clearly don't have experience with legitimately growing corporations. Special legal counsel is a good thing. Law firms and specific lawyers specialize in various things and you want those specialized lawyers helping guide you through any regulatory, sensitive or other important matters because they have the experience of having gone through it many times before, know the key players and more.
Something like a NASDAQ uplisting absolutely requires specialized attorneys and counsel.
I'm long and strong and added a lot of shares on Friday.
This stock is just manipulated because it is on this crap OTC exchange and people who have nothing to contribute see it as a good way to make a quick buck. That's fine, but these are not wealthy people, they are bottom feeders who don't have the money, nor psychological fortitude for real investing medium and short term.
----
CV SCIENCES, INC. CEO ISSUES LETTER TO SHAREHOLDERS
August 12, 2019
SAN DIEGO, Aug. 12, 2019 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products through its industry-dominating brand, PlusCBD™ Oil, today released a letter to shareholders from CEO Joseph Dowling.
Dear Shareholders,
Last week we issued our second quarter results, reporting the highest quarterly revenue in our company’s history, continuing a streak of 14 consecutive quarters of sequential revenue growth. This consistent growth is a reflection of the strength of the PlusCBD™ Oil brand and our growing distribution across retail channels. Year to date, we have more than doubled the number of retail doors where PlusCBD™ Oil products are carried, and we continue to enjoy a strong pipeline of new distribution opportunities. The fundamentals of our business are strong and our opportunity grows daily as consumer demand for hemp-based CBD products continues to expand at a rapid rate. We are proud of our second quarter results, but like you, we are disappointed by the market’s reaction. We pride ourselves on giving comprehensive quarterly updates, and our discussion of increased competition reflects what we see in our business today. But, as I noted on our second quarter conference call, incremental competition may lead to choppy quarter to quarter results. However, it does not detract from the rapidly growing market opportunity and expanding distribution, which along with our continued investments in our brand and industry leading quality, are the foundation of our long-term growth trajectory.
We have worked hard this year to further strengthen our company and fully leverage the power of the PlusCBD™ Oil brand. We have added key leadership talent, invested in systems to strengthen our business processes, broadened our product offering, expanded our supply chain to source domestic hemp and signed a lease to expand our production and warehousing capacity by five-fold. We are investing in consumer research to support a brand refresh and best position our brand for growth. We are also accelerating our Direct-to-Consumer tactics, including a redesign of our PlusCBD™ Oil consumer site and adding tools to accelerate online sales. Additionally, we are actively pursuing new distribution channels to complement our core natural product retailer channel and growing distribution into the food, drug and mass channels. We have a great story to tell…to consumers, to retailers and to investors.
As I recently told CBD Today, “To really compete, you have to have a brand that is respected and trusted, and then you have to have scale. If you don’t have those two things, you’re not going to be able to compete, and we have both. We are the only company with true fundamentals. We’re profitable. We have cash flow, which has allowed us to accumulate more than $15 million cash organically, and we have no debt. We’re more profitable and certainly undervalued when compared with the THC focused cannabis stocks, all of whom say their growth potential is off the charts. We think ours is, too.”
As discussed in our earnings call last week, we continue to raise the bar not just for our company, but the industry as a whole. We appointed Deloitte as our auditors earlier this year and retained special legal counsel to help in our Nasdaq uplist effort, which is a top priority for our company. The company continues to add respected industry leaders to its senior management team. Additionally, CV Sciences has retained other world-class industry experts, including in marketing, sales and e-commerce operations.
CV Sciences pioneered the CBD consumer product industry, and as the regulatory framework emerges, our industry dominance and growth will continue and escalate. We ask that you trust in the long-term vision of this great company, the strong team we have built, and our proven track record of business performance, science-based R&D and regulatory leadership. We believe we are well-positioned to capitalize on the conservatively projected $20 billion plus CBD industry and we look forward to sharing news of future business development successes in the coming months.
Thank you for your continued support.
Sincerely,
Joseph Dowling
Chief Executive Officer
About CV Sciences, Inc.
CV Sciences, Inc. (OTCQB:CVSI) operates two distinct business segments: a consumer product division focused on manufacturing, marketing and selling plant-based CBD products to a range of market sectors; and a drug development division focused on developing and commercializing novel therapeutics utilizing CBD. The Company’s PlusCBD™ Oil is the top-selling brand of hemp-based CBD on the market, according to SPINS, the leading provider of syndicated data and insights for the natural, organic and specialty products industry. CV Sciences, Inc. has primary offices and facilities in San Diego, California. Additional information is available from OTCMarkets.com or by visiting www.cvsciences.com.
FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties.
CONTACT INFORMATION:
Investor Contact:
ICR
Scott Van Winkle
617-956-6736
scott.vanwinkle@icrinc.com
Media Contact:
ICR
Cory Ziskind
646-277-1232
cory.ziskind@icrinc.com
Primary Logo
Source: CV Sciences, Inc.
Released August 12, 2019
The way to prove you are a low-class, unprofessional company is to get into public fights with OTC market manipulators.
Remember, they are trying to prove they are a professional, respectable company that can build a world-class brand. If they go down the road of releasing press and publicly fighting OTC market manipulators it makes them look ridiculous and would only undo all the work they've done, and continue to do, to turn themselves into a respectable brand after all the Mona crap.
They would be a laughingstock if they turn their brand into an OTC market manipulator public battle warrior.
This would hurt brand value and the SP a lot more in the medium and long-term.
A soft statement might be ok, but some on this board want them to reorient their brand to fighting market manipulators. That takes their eye of the ball.
They need to keep their eye on the ball of growth, revenue, NASDAQ, respectability and distribution. This is what a professional company would do.
No matter what they do, they won't win against the OTC manipulators until they are off it and hopefully on NASDAQ.
Bought more today - quite a lot I suppose. Even if it sinks lower, I'm in for another 1-3 years or so regardless of today's, this month's or this year's moves. Good company, but this is just classic OTC behavior. OTC is an awfully volatile place and this is what we get while being on OTC.
If it goes down to below 2s significantly I'll buy another chunk.
Have a good weekend everyone!
We were also green 3-4% yesterday before closing down 5%. I've been buying this morning but holding my gunpowder for later in the day. I don't trust morning moves unless on good, real news.
I have a stack of cash waiting to buy a lot of new shares to add to my already large pile of shares. Going to see what the action is like tomorrow. Don't see why this won't go lower given the manipulation.
If it goes down into the 2s, that would be great to scoop up more - but I'm hoping it holds above 3 for cosmetic sake.
CVSI will have its day in the sun - may just be a few quarters. Or at least until FDA clears a lot up.
We've got a long climb back up. There are some good potential catalysts coming up, but overall, buckle in, put your bare feet up on the dashboard, turn on that classic rock and enjoy the view out of the window for a while.
We've got a nice car, it'll get us there, in my opinion.
(Maybe a dead cat bounce here or there)
I'm not defending today - just noting that it happens and an experienced investor should always be psychologically prepared for days like today when on the OTC.
If an investor is not financially and more importantly, psychologically, prepared to lose 90% of their investment in an OTC stock, they shouldn't be here - period.
I've been through upwards of 40% drops on the OTC - this is what happens here on the OTC.
What's not right here is that people are investing on OTC, in an unregulated, emerging industry and then complaining about irrational behavior - the entire OTC is irrational.
More irrational moves with CVSI will happen at some point. Bank on it. 100%. And everyone's reactions on this board will be the same as today.
They would be insane to sell the company between $4-$8.
If you can afford this, you would not be posting this much saying the same thing over and over again.
OTC message board behavior reveals everyone's wealth and knowledge.
You clearly can't afford the stock value loss you had today. No, they must not sell.
You've been freaking out all day. Seriously, you shouldn't be in this stock or on the OTC if you don't expect things like this to happen and plan for them (or just able to not access this money for a while).
Today shows this:
First my experience with OTC:
My record on OTC companies just like this one is 100%. I like to stay away from OTC. This is my third time investing relatively significant money compared to the middle class, on a previously scammy company that finally hit something right and is in a high-growth emerging US industry with spotty and unanswered regulatory framework.
These are the OTC companies I look for. Of the previous two, one was bought out and the other moved up to NASDAQ where it went on a fantastic run and after a few years on NASDAQ, has settled back down.
Today is classic OTC. You can literally predict that the below will happen with this type of specific OTC company:
- Solid company now, but checkered past
- Irrationally volatile trading through a lot of people looking for quick hits and manipulators
- Trolls coming out of the woodwork to slam the company, annoying everyone (these people have no lives and are deeply unhappy and aren't nearly as successful as they pretend to be on these boards - they live here to feel better about themselves)
- Short-terms freaking out because they invested too much into this and they need that money (These people should be investing on OTC, you need to build generational wealth, not try to hit it big on the OTC...be smart and get out of here and talk to someone who has real wealth and listen to them)
- Longs and ultra-longs sitting back and buying more (like myself) who believe we need to wait through the regulatory questions and wait for the marketplace to establish itself.
Gang - this is going to happen. This is the wild west.
Which category above do you fit into?
I just bought more and I'm not worried. Any stock on the OTC, no matter how good or bad earnings are, does not behave in a rational way like stocks on the big board do.
This year is the 2nd inning for this company.
If you are a multi-year investor (3-5) like I am, this company, in my own personal opinion, is a steal right now.
I'm excited about the future. This company on the OTC, like buying a new puppy or having a new baby, is a complete mess and doesn't act rationally. But you know, or at least hope, in the future they will be a functioning dog/adult.
But this year is a mess, no doubt about it, due to being on the OTC.